Friday, November 24, 2017 4:24:17 PM
Broadly speaking, to the extent Alzheimers arises from insults to the brain rather than fully endogenous reasons, focusing on the gatekeepers to the brain (in microglia) may be a worthy approach to slow down and keep away any onset. Don't think they are addressing mitochondrial repair and any receptor restoration that is essential for any reversal of the condition.
Haven't looked into the backgrounds of the 2 main protagonists but I get scared off when I see someone describe oneself as a serial-entrepreneur esp. if the person is primarily a medical researcher. I prefer the Tasos Zografidis types who confine themselves to research and leave profit-seeking motivation as a responsibility for someone else organizationally.
Never a bright move to buy in so early on an indication that's presented such remote a chance in clinically effective treatment. Could be totally wrong but my gut says it had a lot to do with connections.
Recent AVXL News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2025 02:12:55 AM
- Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease • GlobeNewswire Inc. • 01/15/2025 12:30:00 PM
- New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients • GlobeNewswire Inc. • 01/13/2025 12:30:00 PM
- Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/24/2024 12:00:31 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/23/2024 09:30:33 PM
- Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 12/23/2024 12:30:00 PM
- Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease • GlobeNewswire Inc. • 12/23/2024 12:00:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 • GlobeNewswire Inc. • 12/16/2024 12:30:00 PM
- Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference • GlobeNewswire Inc. • 12/09/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2024 02:00:08 AM
- Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 • GlobeNewswire Inc. • 12/02/2024 12:30:00 PM
- Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA • GlobeNewswire Inc. • 11/26/2024 12:30:00 PM
- Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal • GlobeNewswire Inc. • 11/25/2024 12:30:00 PM
- Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024 • GlobeNewswire Inc. • 10/31/2024 08:00:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition • InvestorsHub NewsWire • 10/23/2024 12:03:31 PM
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
FEATURED Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM
Avant Technologies and Ainnova Begin Implementing and Testing Advanced AI Algorithms for Early Detection of Additional Diseases • AVAI • Jan 16, 2025 8:00 AM
VOCODIA HOLDINGS INC. (OTCMKTS: VHAI) and TRACCOM INC. (OTCMKTS: TRCC) have signed an MOU to form a Joint Venture that will Revolutionize Event Monitoring with Narrative AI • VHAI • Jan 15, 2025 2:53 PM